Abstract:Background: Progressive LV enlargement and dysfunction are characteristics of heart failure (HF) and are associated with increased mortality and morbidity. We tested the hypothesis that selective regional injections of alginate hydrogel implants (AHI, Algisyl-LVR, Lonestar Heart, Inc.) into isolated segments of epicardial veins of the failing LV will increase LV wall thickness and lead to reduced LV size, lower LV wall stress and improved LV systolic and diastolic function. Methods: 12 dogs with coronary microembolization-induced HF (LV ejection fraction, EF<30%) were studied. During an open-chest procedure, 1.5 to 2.0 cm segments of the 2 nd diagonal branch and the 2 nd marginal branch of the cardiac epicardial veins were isolated by ligation with silk sutures. In 6 dogs, the isolated segments were each injected with 1.0 ml of AHI and in 6 dogs with normal saline (controls). LV ED volume (EDV), ES volume (ESV), EF, stroke volume (SV), ED wall stress (EDWS), deceleration time of early mitral inflow velocity (DT), and severity of functional mitral regurgitation (MR) were measured before therapy (Pre) and at 6 months after AHI or saline delivery (Post). The treatment effect (Δ) was calculated as the difference between Pre and Post. Results: In preliminary we showed that an intravenous injection of 1.0 ml AHI increased regional LV end-diastolic (ED) and end-systolic (ES) wall thickness by 5.8 ± 0.7 % and 9.0 ± 1.0 %, respectively. Compared to saline controls, treatment of HF dogs with AHI prevented the increase in EDV and significantly decreased ESV, EDWS and severity of functional MR (Table). In addition, AHI significantly increased LV EF, SV and DT indicating improved LV systolic and diastolic function (Table). Treatment with Alginate implants also showed a safe and non-arrhythmogenic chronic profile. Conclusion: LV reconstruction using selective regional injections of AHI into epicardial cardiac veins represents a safe novel approach for the treatment of advanced chronic HF. Table 1. Hemodynamic and Ventriculographic Results Control (n=6) AHI (n=6) P-Value ΔEDV (ml) 2.5 ± 1.0 −1.1 ± 0.4 0.114 ΔESV (ml) 4.3 ± 1.7 −3.9 ± 0.4 0.001 ΔEF (%) −3.8 ± 1.5 5.0 ± 0.4 0.001 ΔSV (ml) −1.8 ± 0.8 0.11 ± 0.04 0.001 ΔEDWS (gm/cm²) 9.4 ± 6.5 −23.1 ± 4.6 0.006 ΔDT (msec) −4.7 ± 0.4 27.0 ± 4.4 0.001 ΔMR (%) 1.7 ± 0.8 −3.6 ±1.3 0.004

Effect of Passive Cardiac Containment on Ventricular Synchrony and Cardiac Function in Awake Dogs

Clinical Effect of Cardiac Resynchronization Therapy in Patients with Chronic Heart Failure

Ventricular-Arterial Coupling in Patients with Heart Failure Treated with Cardiac Resynchronization Therapy: May We Predict the Long-Term Clinical Response?

Renal sympathetic denervation inhibites the development of left ventricular mechanical dyssynchrony during the progression of heart failure in dogs

Ventricular electrophysiology in congestive heart failure and its correlation with heart rate variability and baroreflex sensitivity: a canine model study.

Effects of Cardiac Resynchronization Therapy on Left Ventricular Remodeling and Dyssynchrony in Patients with Left Ventricular Noncompaction and Heart Failure

A Comparative Study of Systolic and Diastolic Mechanical Synchrony in Canine, Primate, and Healthy and Failing Human Hearts

Effect of Ventricular Assist Device on Improving Cardiac Function in End-Stage Heart Failure

Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices

Dyssynchronous Heart Failure Models in Canines: New Insights into Electrocardiographic, Echocardiographic and Histological Features.

Effect of levosimendan on ventricular systolic synchronicityin chronic heart failure

Short-term mechanical unloading with left ventricular assist devices after acute myocardial infarction conserves calcium cycling and improves heart function

Spinal Cord Stimulation Protects Against Ventricular Arrhythmias by Suppressing Left Stellate Ganglion Neural Activity in an Acute Myocardial Infarction Canine Model.

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Myocardial infarction does not preclude electrical and hemodynamic benefits of cardiac resynchronization therapy in dyssynchronous canine hearts

Abstract P175: Selective Regional Injections of Alginate Hydrogel into Cardiac Veins Improve Left Ventricular Function and Reverse Chamber Remodeling in Dogs with Chronic Heart Failure

Area of Left Ventricular Regional Conduction Delay and Preserved Myocardium Predict Responses to Cardiac Resynchronization Therapy

Myoblast transfer in ischemic heart failure: effects on rhythm stability.

Autologous Skeletal Myoblast Transplantation Improved Hemodynamics and Left Ventricular Function in Chronic Heart Failure Dogs.

Improved Left Ventricular Function in Chronic Heart Failure Dogs by Skeletal Autologous Myoblast Transplantation